Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Total Non-Current Liabilities (2016 - 2025)

Editas Medicine (EDIT) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $183.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 23.52% to $183.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $183.6 million, a 23.52% increase, with the full-year FY2024 number at $204.2 million, up 37.76% from a year prior.
  • Total Non-Current Liabilities was $183.6 million for Q3 2025 at Editas Medicine, down from $186.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $204.2 million in Q4 2024 to a low of $142.5 million in Q1 2024.
  • A 4-year average of $168.0 million and a median of $153.6 million in 2022 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: fell 3.5% in 2023, then soared 37.76% in 2024.
  • Editas Medicine's Total Non-Current Liabilities stood at $153.6 million in 2022, then dropped by 3.5% to $148.3 million in 2023, then soared by 37.76% to $204.2 million in 2024, then fell by 10.1% to $183.6 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Total Non-Current Liabilities are $183.6 million (Q3 2025), $186.8 million (Q2 2025), and $194.9 million (Q1 2025).